Can low choline/betaine drive high homocysteine even with normal folate and B12?

The maintenance of healthy homocysteine levels relies on two distinct but complementary remethylation pathways. While the folate and vitamin B12-dependent pathway is the most recognized, the betaine-homocysteine S-methyltransferase (BHMT) pathway provides a critical secondary mechanism that utilizes betaine—derived from dietary choline—to convert homocysteine back to methionine.

Clinical and effectiveness evidence

Research demonstrates that choline and betaine intake are inversely associated with plasma homocysteine levels, independent of folate and vitamin B12 status.

• Choline deficiency impact: In clinical studies of healthy adults, a choline-deficient diet has been shown to increase fasting plasma homocysteine by approximately 35% and double post-methionine load homocysteine levels, even when B-vitamin levels remain within normal ranges.
• Supplementation effects: Randomized controlled trials indicate that betaine supplementation (typically ≥4 g/day) can lower fasting homocysteine by 10–15% and post-prandial (after a meal) homocysteine by 20–40% in individuals with adequate folate.
• Population studies: Data from large cohorts show that individuals with the highest intakes of choline and betaine have significantly lower homocysteine concentrations compared to those with the lowest intakes, regardless of their B-vitamin status.

Mechanistic explanations

The BHMT pathway serves as a metabolic "sink" for homocysteine, primarily located in the liver and kidneys.

• Enzymatic pathway: BHMT catalyzes the transfer of a methyl group from betaine (trimethylglycine) to homocysteine. This reaction produces methionine and dimethylglycine (DMG).
• Pathway capacity: In the liver, the BHMT pathway is highly active and can account for up to 50% of total homocysteine remethylation.
• Compensatory role: When the folate/B12-dependent pathway (methionine synthase) is saturated or under stress—such as after a protein-rich meal—the body relies heavily on BHMT. If choline or betaine demand is high or supply is low, this secondary pathway fails to clear excess homocysteine, leading to elevation despite normal B-vitamin levels.

Clinical implications

For individuals with persistently elevated homocysteine despite optimal folate and B12 levels, assessing choline and betaine status is a necessary clinical step. This is particularly relevant for those with higher physiological demands for methyl donors or genetic polymorphisms (such as in the MTHFR or BHMT genes) that may increase reliance on the betaine-dependent pathway.

Bottom line

The claim is strongly supported by biochemical and clinical evidence. Choline and betaine act as independent regulators of homocysteine; therefore, insufficient levels can cause elevated homocysteine even when folate and vitamin B12 status are normal.